🇺🇸 Tissue Plasminogen Activator in United States

133 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Angioedema — 18 reports (13.53%)
  2. Cerebrovascular Accident — 17 reports (12.78%)
  3. Cerebral Haemorrhage — 16 reports (12.03%)
  4. Haemorrhage Intracranial — 16 reports (12.03%)
  5. Dyspnoea — 12 reports (9.02%)
  6. Haematoma — 12 reports (9.02%)
  7. Death — 11 reports (8.27%)
  8. Drug Ineffective — 11 reports (8.27%)
  9. Condition Aggravated — 10 reports (7.52%)
  10. Drug Interaction — 10 reports (7.52%)

Source database →

Tissue Plasminogen Activator in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Tissue Plasminogen Activator approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Tissue Plasminogen Activator in United States?

Brigham and Women's Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.